STOCKHOLM, March 30, 2022 /PRNewswire/ — Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharmaceutical company developing modifying treatments for Alzheimer’s disease, today announced that the manufacturing process for its oligomer-specific vaccine, ALZ-101, has been further improved for full-scale production.
Alzinova’s drug manufacturing partner, Bachem (Bubendorf, Swiss), optimized the manufacturing process for the active ingredient of ALZ-101, a vaccine in clinical development for the treatment of Alzheimer’s disease. Process optimizations resulted in a more efficient and scalable manufacturing process enabling the supply of ALZ-101 in the quantities required for Phase 2 clinical trials. Additionally, a more robust manufacturing process was achieved, which is beneficial for future reliable, cost effective and GMP (good manufacturing practice) manufacturing.
“We are very pleased to have reached this milestone, which is part of preparing the therapeutic vaccine, ALZ-101, for phase 2 and more attractive to potential partners,” said Kristina Torfgård, CEO of Alzinova AB. .
In the third quarter of 2021, Alzinova initiated a phase 1b clinical study with ALZ-101, in patients with Alzheimer’s disease. The vaccine is developed to specifically target neurotoxic soluble forms of amyloid-beta42, i.e. oligomers. Oligomers are considered a key factor in the development of Alzheimer’s disease. The first data from the study are expected in the second half of 2023.
For more information please contact:
Kristina Torfgard, CEO
Such. +46 708 46 79 75
E-mail: [email protected]
The information has been submitted for publication, through the contact person listed above, to 08:01 CEST on March 30, 2022.
About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharmaceutical company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid beta-oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer’s disease. Alzinova’s patented AβCC peptide™ technology enables the development of disease-modifying therapies that target toxic amyloid beta-oligomers implicated in disease onset and progression with high precision. Alzheimer’s disease is one of the most common and devastating neurological diseases in the world, with an estimated 40 million people affected today. Additionally, the ALZ-201 antibody is in early preclinical development, and the ambition is to further expand the pipeline. The company’s certified advisor on the Nasdaq First North Growth Market is Corpura [email protected] +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download: